Purpose: Isolated limb perfusion (ILP) with tumor necrosis factor (TNF), interferon gamma, and melphalan (M) has been reported to result in high response rates for extremity melanoma and sarcoma. We have evaluated the relationship of systemic TNF exposure to induction of several secondary mediators and incidence of systemic toxicity.
melanomas with ILP, although the benefit of this treatment on overall survival has not been clearly established. 2 , 5 , 6 In patients with assessable disease, therapeutic M ILP has resulted in complete response (CR) rates that range from 10% to 82%.7 This wide range of responses may be due to clinical variables such as M dose, duration of perfusion, site of the tumor (upper v lower limb), nodal status, and degree of hyperthermia. Tumor necrosis factor (TNF) has been shown in several animal models to produce a dose-dependent response, with acute tumor necrosis followed by complete tumor regression.9-' Extension of these preclinical studies to patients resulted in significantly lower maximal-tolerated doses in patients (8 to 10 jg/kg)12-14 compared with mice (400 Mg/kg),'o with a corresponding decrease in response. Regional administration allows increased local TNF levels, and direct intratumoral injection of TNF has induced a higher rate of objective tumor regression." Isolated perfusion is another method to provide intravascular delivery of high-dose TNF' 6 to the tumor while limiting systemic exposure. In initial studies, Lienard et ai16" 7 added high-dose TNF and interferon gamma to ILP with M (TNF/IFN/M) and hyperthermia to treat patients with stage III extremity melanoma or sarcoma and reported a 92% CR rate.'"
The combined European experience with this treatment regimen currently includes more than 100 patients with extremity melanoma or sarcoma. Their overall response rates are 90% CRs and 10% partial responses (PRs) for melanoma, and 46% pathologic CRs and 54% PRs with sarcomas (A.M.M. Eggermont, personal communication, September 1994). Systemic toxicity from ILP with TNF may be the consequence of a leak from the perfusion circulation into the systemic circulation. In the reported experience, transient hypotension, fever, and chills occurred in all patients, with significant pulmonary (acute respiratory distress syndrome [ARDS] , temporary ventilator dependence), hepatobiliary (jaundice), and renal toxicities also reported.'6'-" Surprisingly, no correlation was found between leak from the perfusion circulation, systemic TNF levels, and systemic toxicity.' 8 TNF induces the production of several secondary mediators, including inflammatory cytokines and cellular adhesion molecules, which may affect systemic toxicity and tumor response. We evaluated the serum levels of several TNF-inducible proteins (interleukin-1 [IL-1], IL-4, IL-6, IL-8, intracellular adhesion molecule [ICAM] , TNF, and TNF-receptor) in both the perfusion and systemic circulations after ILP with TNF/IFN/M compared with M alone. We also compared levels in patients with or without a leak from the perfusate as measured by continuous intraoperative monitoring with radioactive iodine-131 albumin. The impact of these mediators on local and systemic toxicity and response rates was evaluated.
PATIENTS AND METHODS
All patients who underwent ILP at the National Institutes of Health from June 1992 to February 1993 and who received TNF doses of 3 or 4 mg or M alone were evaluated. These patients were treated on one of two ongoing clinical trials. A phase II trial in melanoma or sarcoma patients evaluates the response to ILP with TNF/IFN/M and hyperthermia. These patients had advanced extremity melanoma or sarcoma and had either failed to respond to other therapeutic options, including previous M perfusion, or refused amputation for large sarcomas in which tumor resection with limb salvage was not an option. Patients with stage IIIA or IIIAB extremity melanoma according to the MD Anderson staging system (stage IIIA, metastases in-transit; stage IIIAB, metastases in-transit and regional lymph node disease) are treated in a phase III trial and randomized to receive ILP with M alone or TNF/IFN/M. Patients were a mean age of 53 ± 15 years (range, 27 to 84 y). The clinical profiles of the 12 patients treated with TNF/IFN/M and seven treated with M alone are listed in Table 1 .
ILP Procedure and Drug Administration
The treatment protocol was identical to that reported by Lienard et al. ' 6 Patients were given interferon gamma (Actimmune; Genentech, San Francisco, CA) subcutaneously (0.2 mg) and in the perfu- Patients underwent ILP with surgical isolation of the axillary artery and vein for the upper extremity, and external iliac artery and vein for the lower extremity. A standard extracorporeal circuit consisting of a roller pump, membrane oxygenator, heat exchanger, and blood filter was used. The circuit was primed with an initial volume of 700 mL of normal saline and 300 mL of packed RBCs. Once isolation was obtained, perfusion flow rates of 300 to 500 mL/min for the upper extremity and 400 to 800 mL/min for the lower extremity were used. The tissue temperature was monitored with four thermistor probes placed in the proximal and distal limb in subcutaneous and intramuscular positions, with tissue temperature maintained between 38.5°C and 40"C during the treatment period. Continuous intraoperative monitoring for a leak from the perfusion circulation was performed using a strip chart recorder connected to a scintillation probe (mobile thyroid uptake system model 7350; Canberra Industries, Inc, Meriden, CT) placed in a precordial position as previously described." 9 After an initial background reading, 20 pCi of I"'-labeled human serum albumin (Merck-Frosst, Quebec, Canada) was injected into the systemic circulation. This resulted in a significant increment and calibrated the leak measurement for that particular patient. After a stable reading was established, 200 pCi of I"' human albumin was injected into the perfusion circuit, and the patient monitored for 10 minutes to evaluate the degree of leak from the perfusate circulation into the systemic circulation. Leak from the isolated limb to the systemic circulation was calculated by the following formula: ([systemic counts at time x/systemic counts at time 0] -1)/10 x 100%. This adjusts for the relative amount of IV` in the systemic and perfusate circulations, but does not consider the volumes of distribution. Further dissection or adjustments in the tourniquet were made if necessary to achieve a calculated leak rate of less than 1% over 10 minutes. Interferon gamma and TNF were given by slow injection into the arterial line of the perfusion circuit. After 30 minutes of perfusion, M was given into the perfusion circuit for an additional 60 minutes with a total perfusion time of 90 minutes. After the perfusion a wash-out procedure was performed with 1,500 mL of crystalloid and 1,500 mL of colloid. Blood was sampled from both the systemic and perfusate circulations at times 0, 15, 30, 60, and 90 minutes from the start of the perfusion, and systemic samples were obtained at intervals during the first 24-hour postoperative period. Samples were kept on ice, and the serum was separated and aliquoted into multiple vials to prevent repeated freeze-thaw cycles and stored at -70'C. Proteins measured by enzyme-linked immunosorbent assay included TNF, leukemia inhibitory factor, ILla, IL-4 (R&D, Minneapolis, MN), IL-6, IL-1/ (Endogen, Boston, MA), IL-8, ICAM, and the soluble 55-kd TNF-receptor (TNF-RI; Biosource, Camarillo, CA). The limits of detection were as follows: TNF, 7.5 pg/mL; IL-6, 4 pg/mL; ICAM, .5 ng/mL; IL-8, 11 pg/mL; TNF-R1, 80 pg/mL; LIF, 4 pg/mL; IL-la, .2 pg/mL; IL-1l, 4 pg/ mL; and IL-4, 4.1 pg/mL. Serum samples were also counted in a gamma counter to determine 1131 counts to confirm leak rates measured by the continuous intraoperative monitoring.
Postoperative Care and Follow-Up
All patients were managed in the intensive care unit during the postoperative period. Significant systemic arterial hypotension was defined as a systolic blood pressure (SBP) of less than 90 mm Hg as measured by an arterial line, and dopamine was started when the SBP was --90 mm Hg and not responsive to volume resuscitation. Patients were evaluated for other signs and symptoms of systemic toxicity graded by the National Cancer Institute common toxicity criteria. Patients returned for postoperative clinic visits 6 weeks, and 4, 8, and 12 months after the perfusion, at which time response within the perfusion field was assessed. A CR was defined as the complete disappearance of all clinical disease. A PR was defined as a greater than 50% decrease in the sum of the products of perpendicular diameter of all measurable lesions without the appearance of new lesions. Patients with sarcoma who did not have concurrent systemic metastases underwent tumor resection 8 to 10 weeks postperfusion. In resected sarcomas, complete necrosis of the residual mass on histologic examination was considered a pathologic CR.
Statistics
Cytokine results are expressed as the mean -SE. The Wilcoxon rank-sum test was used for nonparametric comparisons, and Fisher's exact test was used for comparison of ratios.
RESULTS

Continuous Intraoperative Monitoring
Continuous intraoperative monitoring (CIM) of I"31-labeled albumin provided a sensitive measurement of leak from the perfusion circuit into the systemic circulation. Leaks as small as 1% could be reliably measured, with good correlation between the percentage leak measured intraoperatively and that calculated by counting serum samples in a gamma counter. Nine patients had no detectable leak, nine had leaks of 1% to 5%, and one patient given M alone had a leak more than 5%. To evaluate the effect of leak on cytokine levels and toxicity, patients who received TNF were classified into two groups, -1% or less than 1% leak, with six patients in each group (Fig 1) . In patients with no leak, there was a slight decrease in systemic 1131 counts, which probably reflected either some distribution of 1131 into tissues over time or volume expansion with intravenous fluids during ILP. Patients who received M alone (n = 7) were analyzed as a third group.
Cytokine Concentrations
TNF was detectable in the systemic circulation during the perfusion in 10 of 12 patients who received TNF. Systemic TNF levels after perfusion increased in most patients, despite the 3-L wash-out performed at the end of the perfusion. Patients with leaks of > 1% had significantly higher peak systemic serum TNF concentrations during perfusion than patients without leaks (2.8 ± 1.0 ng/mL v 0.7 + 0.5 ng/mL; P = .027), with a further increase in systemic TNF levels after perfusion of 8.2 ± 2.8 and 2.0 -0.7 ng/mL, respectively (P = .05) (Fig  2A) . All patients had systemic TNF levels less than 0.02 ng/mL by 6 hours postoperatively. Perfusate serum TNF levels stayed relatively constant during perfusion, with mean concentrations significantly lower in patients with a leak (2,670 ± 308 ng/mL v 3,778 + 380 ng/mL; P = .01) (Fig 2B) . There was no measurable serum TNF in any patient perfused with M alone.
Baseline serum IL-6 concentrations were 0 to 30 pg/ mL in all but one patient, in whom the pretreatment level was 111 pg/mL. Systemic IL-6 concentrations increased significantly in all patients compared with baseline (P < .001), with peaks occurring 4 to 6 hours after the start of perfusion. The increase was significantly greater in patients perfused with TNF/IFN/M compared with M alone (12,395 + 3,128 pg/mL v 79 + 23 pg/mL; P < .001) (Fig 3A) . There was a trend toward higher IL-6 levels in patients with a leak, although this difference was not statistically significant (Table 2) . Perfusate IL-6 concentrations were evaluated before the addition of TNF and at the end of the 90-minute perfusion. Although IL-6 levels increased in the perfusate with M alone (539 ± 192 pg/mL), this increase was significantly less than with TNF/IFN/M (7,248 ± 563 pg/mL) (Fig 4A) .
Serum ICAM levels remained stable in the systemic or perfusate circulations of patients who underwent ILP with M alone. However, significant increases did occur in the systemic circulation after perfusion with TNF/IFN/ M (266 ± 16 v 539 + 50 ng/mL), with systemic levels reaching maximum at 8 to 12 hours after perfusion. There were no differences between those with leak and those without (Fig 3B) . Perfusate levels were slightly elevated in all groups (Fig 4B) .
Levels of IL-8 in our patients increased slightly, except in one patient who had a marked increase to a level of 1,115 pg/mL 2 hours after the start of ILP. The increase in systemic IL-8 levels was significantly greater in patients who received TNF/IFN/M, increasing to 312 ± 113 pg/mL versus 20 ± 10 pg/mL with M alone (P = .001), with peak levels measured 2 to 3 hours after the start of perfusion. Perfusate levels were also higher with TNF (192 ± 52 pg/mL v 30 ± 8 pg/mL; P < .001), and were highest in TNF patients with no measurable leaks (297 + 86 pg/mL v 87 ± 13 pg/mL; P = .002) (Fig 5) . "tMeasured 2 to 3 hours after start of perfusion.
tMeasured > 6 hours after the start of perfusion when serum TNF levels < 100 pg/mL. §P < .05 v no leak. ¶P < .01 v no leak.
"lP < .01 v all TNF. "**P < .001 v all TNF.
Serum samples that contained TNF levels less than 100 pg/mL were assayed for soluble 55-kd TNF-receptor (TNF-R1) levels. Previous assays for soluble TNF-receptor showed no interference with measurement of TNF-R1 at TNF levels s 195 pg/mL (Biosource, unpublished data). The normal range for TNF-RI serum is 1.4 to 4.16 ng/mL. 30 One patient had an elevated baseline level of 11.27 ng/mL, while the remainder had levels < 3 ng/mL. Six hours after perfusion with TNF/IFN/M, the levels of TNF-Rl had increased 3.2 + .5 ng/mL, compared with an increase of 1.0 ± .2 ng/mL in M-alone patients (P = .026) (Fig 6) . A limited number of samples were tested for other cytokines, with negative results. IL-la, IL-1/, IL-4, and LIF were not detected in the serum from selected patients perfused with TNF/IFN/M or M alone.
Toxicity and Response
The most frequent systemic toxicities were fever and hypotension. All patients who received TNF/IFN/M had a fever the night of surgery, with temperatures ranging from 38 to 40.1 0 C (mean, 39 + V1C), while the patients who received M alone had maximal temperatures of 37 + 0.3oC. Only patients who received TNF who had measurable leaks developed hypotension. This toxicity began 3 to 13 hours postoperatively and required a maximal dopamine dose of 3 to 10 jg/kg/min (mean, 7.6 gg/kg/ min) for 7 to 24 hours (mean, 16); phenylephrine was needed in one patient. Other systemic toxicities included thrombocytopenia (platelet count < 100,000/jiL) in three patients and hyperbilirubinemia (total bilirubin level > 2 mg/dL) in one patient. This last toxicity occurred in a patient who had received TNF/IFN/M with a leak of 2% and elevated baseline IL-6 and TNF-R1 levels. No clinically significant pulmonary toxicity was seen in any patient. Regional toxicity was not different between patients who received TNF/IFN/M versus M alone, and included grade II skin toxicity (six of 12 v four of seven patients), grade 1 edema (four of 12 v five of seven), and grade 1 neuropathy (three of 12 v two of seven). than those used in animal models. Lienard et al' 6 first reported the administration of high concentrations of TNF using ILP with acceptable systemic toxicities and dramatic tumor necrosis in melanomas and sarcomas, and a 100% response rate and 90% CR rate. 16 We have repro- duced their protocol, with similar tumor response rates and less systemic toxicity. The dose of TNF we administered achieved TNF concentrations in the perfusion circulation that were approximately 300-fold higher than could be achieved after an intravenous infusion of TNF. 23 These extremely high TNF levels are sustained throughout the 90-minute perfusion period, with no additional regional toxicity.
The differences in perfusate TNF concentrations were significantly higher in the patients with no leak versus leak during ILP. However, these difference do not represent the amount of TNF released into the systemic circulation, but reflect the relatively higher concentration of TNF in the perfusate of three patients who underwent arm ILP. Complete vascular isolation of an arm during ILP can be achieved fairly routinely, and all three patients who underwent arm ILP had less than 1% leak. Although the dose of TNF for arm ILP is 3 mg compared with 4 mg for leg ILP, in general, the intravascular volume of the arm is considerably less than 75% of the leg. Because the priming volume of the perfusion circuit is constant for arm or leg ILP, the smaller arm volume will result in higher perfusate concentrations of TNF.
Endogenous TNF production is an early host response to infection that leads to septic shock in severe cases. Systemic administration of exogenous recombinant human TNF has also been shown to induce similar hemodynamic and systemic changes in experimental animal models 24 -26 and humans. 22 In these models, increased circulating TNF levels are followed by a cascade of transient increases in circulating levels of several cytokines in sequence. These cytokines in turn modulate toxicity and may have undefined roles in TNF-mediated tumor regression. Despite the lack of systemic toxicity associated with systemic administration, ILP with high-dose TNF may mimic part of this host response, with systemic metabolic or immunologic effects attributible to TNFinduced proteins. Circulating lymphocytes, 27 monocytes, 28 and platelets, as well as vascular endothelial cells, 2 9 -31 normal soft tissue, 32 and tumor, 3 3 all respond to TNF in vitro. Similar responses may occur in these cells located in the perfused extremity in vivo after exposure to very high TNF levels. A more generalized systemic response may also be seen from exposure to the lower levels of circulating systemic TNF that may occur or from the TNF that is released after restoration of normal circulation to the perfused limb. Fever and chills occurred in all patients who received TNF/IFN/M and none who received M alone. Hypotension was seen only in patients with leaks from the perfusate during the perfusion as measured by continuous intraoperative monitoring, with these patients having significantly higher systemic TNF levels. One previous report on ILP with TNF has shown poor correlation between leakage, peak TNF levels, and systemic toxicity.'" Our patients, on average, had smaller leaks, with leaks of less than 5% in all TNF-treated patients, whereas previous reports included eight of 1818 or 12 of 2316 patients with leaks more than 5%. We saw correspondingly fewer toxic side effects, with no patients developing ARDS, hypoxia, or renal failure. We used dopamine therapeutically, and only started it when the SBP decreased to 90 mm Hg, whereas others have used it prophylactically in all patients. Thus only half of the patients in this series treated with TNF required vasopressors in the postoperative period, and these patients had significantly higher systemic serum TNF levels than those without leaks and hypotension. The TNF concentrations of 2 to 5 1 ug/mL in the perfusate were similar to those previously reported, 1 6 ' 18 with similar response rates. IL-6 has pleiotropic effects on the immune system 34 and on acute-phase and inflammatory responses. 35 These systemic responses may aid in the host defense against tumors by stimulating lymphocyte differentiation and antibody production, or by enhanced hematopoiesis with increased monocyte, granulocyte, and megakaryocyte production. IL-6 may have direct antitumor effects as well, acting as a growth inhibitor in some carcinoma cell lines. 36 Studies have shown a decreased number of metastasis with increased survival in tumor-bearing mice treated with IL-6.37-39 Although a small increase in serum IL-6 levels occurred when ILP was performed with M alone, a significantly greater increase was seen after TNF perfusion, with a trend toward higher levels in patients with increased systemic exposure to TNF. IL-6 levels in the perfusate at the end of the 90-minute perfusion were significantly greater with TNF/IFN/M than with M alone, and were greater than the simultaneous systemic levels. The systemic levels continued to increase after the perfusion, and reached a peak approximately 4 hours after the start of perfusion. This time course of elevated levels and the maxi-mal levels reached in our study are similar to those seen when TNF was administered systemically to patients."4 The European experience with TNF limb perfusion was associated with significant pulmonary toxicity, including ARDS, and IL-8 and ICAM have both been implicated as mediators of pulmonary injury after TNF exposure. 4 1 " 42 IL-8 is a potent neutrophil chemotactic factor released by several cell types, including endothelial cells; it also stimulates neutrophil transmigration43 and has been shown to be chemotactic for T cells. Studies of normal volunteers who received intravenous endotoxin to produce peak serum TNF levels of 3 ng/mL have found IL-8 levels of 600 to 800 pg/ mL 2 to 3 hours after endotoxin administration In our study, significantly increased levels of IL-8 occurred after TNF perfusion, without any associated pulmonary toxicity. ILP with TNF also resulted in a significant increase in the levels of IL-8 in the perfusate. A dose-response to TNF was seen to some degree, with a greater increase occurring in patients without measurable leak who had correspondingly higher perfusate TNF levels.
ICAM is expressed on endothelial cells, 45 
5
" ICAM-1-induced activation of neutrophils has also been implicated in pulmonary vascular injury and edema during sepsis. 42 The increased circulating levels of ICAM found in our study were not associated with identifiable toxicity, and may represent protein released by circulating leukocytes, released by the endothelial cells in the perfused extremity or shed from tumor cells. The importance of these increased levels in terms of tumor response or toxicity remains to be determined.
Increased serum levels of soluble TNF-receptor have been reported in patients with a variety of advanced cancers51 and after endotoxin administration to normal volunteers.52 One patient in our study had increased soluble TNF-R1 and IL-6 levels before perfusions and had slightly greater systemic toxicity. Only slight increases were seen in all patients after TNF perfusion, although the increase was significantly greater after ILP with TNF/IFN/M than with M alone.
TNF clearly induces the production and release of IL-1 from monocytes and endothelial cells in vitro, 5 3 and although increased circulating levels have been reported after major surgery" and systemic TNF administration, this has not been a consistent finding. We did not find any detectable levels in perfusate or systemic circulations. Similarly, IL-4 and LIF were not measurable in several samples from TNF/ IFN/M perfusions.
In summary, ILP with high-dose TNF/IFN/M can be performed with regional toxicity similar to that after perfusion with M alone. Systemic toxicity was limited to postoperative fever and transient hypotension in some patients. The addition of TNF and interferon gamma to ILP with M resulted in significant differences in host response as evidenced by differences in systemic cytokine release, including IL-6, ICAM, IL-8, and soluble TNF-R1. With the exception of serum TNF levels, cytokine levels were not significantly different when incomplete limb isolation occurred, despite the difference in SBP response. Continuous intraoperative monitoring with 1131 albumin provides a sensitive and accurate method of detecting leak from the perfusion circuit. A leak of Ž 1% can be measured with this system and predicts the development of transient hypotension approximately 6 hours after perfusion with TNF. Patients with no measurable leak did not develop hypotension and had significantly lower peak systemic TNF levels. Continued patient accrual to these studies and longer follow-up durations are needed to evaluate fully the therapeutic benefit of this treatment regimen.
